Authors

Joshua Brody, MD, of Mount Sinai Hospital

Latest:

Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD

Chandler Park, MD and Joshua Brody, MD discusses treatment challenges posed by the diverse spectrum of lymphomas, ranging from indolent subtypes, to aggressive diseases like Burkitt lymphoma.

Joshua Brody, MD, Icahn School of Medicine at Mount Sanai

Joshua D. Waltonen, MD, Christopher A. Sullivan, MD

Latest:

Transoral Surgery for Oropharyngeal Squamous Cell Carcinoma

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been steadily increasing over the last few decades, mostly due to HPV, which is now associated with the majority of newly diagnosed cases of OPSCC.

Joshua G. Cohen, MD, FACOG, FACS

Latest:

Dr Cohen on Key Trials Supporting the Use of PARP Inhibitors in Ovarian Cancer

Joshua G. Cohen, MD, FACOG, FACS, discusses key trials supporting the use of PARP inhibitor maintenance therapy in upfront setting in ovarian cancer.

Joshua Howell

Latest:

Clinical Decision Support Tools Deliver Benefits Beyond Improved Patient Care

One best practice identified for transforming quality, safety and efficiency in healthcare is the use of clinical decision support tools.

Joshua J. Meeks, MD, PhD

Latest:

Dr Meeks on Harnessing Innovation in Bladder Cancer

Joshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.

Joshua K. Sabari, MD

Latest:

Dr Sabari on the FDA Approval of Amivantamab/Lazertinib in EGFR+ Advanced NSCLC

Joshua K. Sabari, MD, discusses FDA approval of first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

Joshua M. Bauml, MD, Perelman School of Medicine

Latest:

Current and Future Use of MET Inhibitors in NSCLC

Healthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.

Joshua M. Bauml, MD, Rena Rowan Breast Center

Joshua M. Bauml, MD, University of Pennsylvania

Joshua M. Lang, MD

Latest:

Need for Dynamic, Predictive Biomarkers Remains Pressing

Despite advances, the majority of patients receiving targeted therapies do not experience radiographic responses, and nearly all patients who initially benefit develop resistance in less than two years.

Joshua M. Lawrenz, MD

Latest:

Dr. Lawrenz on Patient Feedback of Preoperative 5-Fraction RT Sarcoma Study

Joshua M. Lawrenz, MD, discusses patient feedback of a study on preoperative 5-fraction radiation therapy for soft tissue sarcoma with immediate resection.

Joshua Meeks, MD, PhD

Latest:

Dr. Meeks Discusses Smoking Status in Bladder Cancer

Joshua Meeks, MD, PhD, assistant professor of urology, biochemistry, and molecular genetics, Northwestern University Feinberg School of Medicine, section chief of robotic surgery, Jesse Brown VA Medical Center, discusses the role of smoking status in the diagnosis of bladder cancer.

Joshua P. Sasine, MD

Latest:

Dr. Sasine on CAR T-Cell Therapy in Ovarian Cancer

Joshua P. Sasine, MD, medical director, Chimeric Antigen Receptor T-Cell Program, David Geffen School of Medicine, University of California, Los Angeles, discusses chimeric antigen receptor (CAR) T- cell therapy in ovarian cancer.

Joshua P. Sasine, MD, PhD

Latest:

Dr Sasine on the Potential Use of Cilta-Cel in Earlier Lines for Multiple Myeloma

Joshua P. Sasine, MD, PhD, discusses the potential role of cilta-cel in earlier lines of therapy for patients with multiple myeloma.

Joshua Richter, MD

Latest:

Dr Richter on Ongoing Research With Bispecific Antibodies in R/R Multiple Myeloma

Joshua Richter, MD, discusses ongoing or upcoming research with bispecific antibodies in relapsed/refractory multiple myeloma.

Joshua Roth, PhD

Latest:

The Design Behind the Development of a Novel-Risk Prediction Model in Lung Cancer Screening

Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the design of a novel risk-prediction algorithm in the context of screening patients for lung cancer.

Joshua Sabari, MD

Latest:

Exciting NSCLC Data Updates from ESMO 2022

The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.

Joyce A. O

Joyce A. Oâ€™Shaughnessy, MD, US Oncology